PDCD1 and hepatocellular carcinoma: Immunotherapy, particularly using immune checkpoint inhibitors (ICIs) like programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies, represents a significant breakthrough in treating solid tumors, including HCC [3].